eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapiesLise Boussemart, Stéphan Vagner, Christine Basmadjian et al.|Nature|2014Cited by 361
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanomaMichaël Cerezo, Caroline Robert, Ramdane Guemiri et al.|Nature Medicine|2018Cited by 265
Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF HeterodimerizationLise Boussemart, Caroline Robert, Isabelle Girault et al.|Cancer Research|2016Cited by 51